Early Identification and Evaluation of Cyclophosphamide Cardiotoxicity

Hematopoietic Stem Cell Transplantation Clinical Trial

— EIECC  

Official title:

Early Identification and Evaluation of the Cardiotoxicity of Cyclophosphamide in Hematopoietic Stem Cell Transplantation : Based on Spot Tracking Ultrasound

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05150080
• Other study ID #: QianfoshanH-210118
• Status: Recruiting
• Start date: July 10, 2021
• Est. completion date: June 1, 2022

Study information

• Verified date: November 2021
• Source: Qianfoshan Hospital
• Contact: MU Kai
• Phone: 15634883957
• Email: mkbest[@]yeah.net
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Hematopoietic stem cell transplantation is an important method for the treatment of hematological diseases and cyclophosphamide is a commonly used chemotherapeutic agent for transplant pretreatment. The incidence of severe cardiovascular events after high-dose cyclophosphamide exposure ranges from 7% to 28% with mortality from 11% to 43%. Thus, an non-invasive, sensitive and reliable method in detecting cardiac function is significant to balance the cardiac risk and the potential cancer treatment benefits. In previous studies, we demonstrated that strain values analyzed by speckle tracking echocardiography decreased significantly after high-dose cyclophosphamide exposure, even though left ventricular ejection fraction remained stable and within normal range. We follow up the hematopoietic cell transplantation patients with cyclophosphamide: to analyze the cut-off values of the parameters of speckle tracking multilayer analysis in predicting early cardiotoxicity induced by cyclophosphamide; to detect the cut-off values of the plasma miRNAs levels in predicting early cardiotoxicity induced by anthracycline.

The purpose of our study is to find out non-invasive, reliable and sensitive echocardiographic parameters and plasma biomarkers for early detection and prediction cyclophosphamide -induced cardiac toxicity and to be helpful to target patients at high risk of cardiotoxicity, who could benefit from closer monitoring or earlier initiation of cardioprotective therapy.

Description:

After obtaining the informed consent of the research subjects, collect the following data of the research subjects: demographic information, clinical symptoms, family history and clinical diagnosis. Patients were tested for troponin, atrial natriuretic peptide, concurrent conventional electrocardiogram, conventional echocardiogram, speckle tracking echocardiography at spots 1 day before cyclophosphamide treatment, 2 days after cyclophosphamide infusion, and 10 days after cyclophosphamide infusion. ethylenediaminetetraacetic acid anticoagulated whole blood were saved and extract the blood cells from the sample bank and freeze them for RNA sequencing. The two-dimensional cardiac ultrasound image acquisition complies with the guidelines of the American Echocardiography Association, and the two-dimensional speckle tracking echocardiography acquisition is 4 cardiac cycles. If a cardiotoxic event occurs during this period, an electrocardiogram, conventional echocardiogram, and speckle tracking echocardiography should be performed within 24 hours.

Analyze the correlation between miRNA and clinical events of cardiotoxicity, and evaluate the predictive threshold of cardiotoxicity in children with high-dose cyclophosphamide chemotherapy.Evaluate the weight of miRNA in predicting cardiac damage, combined with serum biomarkers, construct a model for Predicting the risk of myocardial damage based on speckle tracking echocardiography parameters, serum biomarkers, and miRNA expression.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: June 1, 2022
• Est. primary completion date: April 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 14 Years

Eligibility

Inclusion Criteria:

• Age =14 years old;

• Bone marrow/umbilical blood HCT received high dose cyclophosphamide(>120mg/kg) ;

• ECOG=2;

• Sign an informed consent form (<10 years old, signed by the guardian; =10 years old, signed by the child and guardian).

Exclusion Criteria:

• Past myocarditis, cardiomyopathy, valvular heart disease, rheumatic heart disease, severe arrhythmia, heart failure, congenital heart disease history;

• Have heart or pericardial surgery;

• Have received radiotherapy involving thoracic cavity;

• Those who do not meet the above entry criteria.

Related Conditions & MeSH terms

• Cardio-oncology
• Cardiotoxicity
• Cyclophosphamide
• Echocardiography
• Hematopoietic Stem Cell Transplantation
• Neoplasms

Locations

Country	Name	City	State
China	Qianfoshan Hospital (The First Affiliated Hospital of Shandong First Medical University)	Jinan	Shandong

Sponsors (1)

Lead Sponsor	Collaborator
Kai Mu

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	changes of global longitudinal strain value between cardiotoxicity group and No cardiotoxicity	changes of global longitudinal strain value between cardiotoxicity group and No cardiotoxicity at the follow-up point	From the start of cyclophosphamide injection to1 month after the completion of injection
Secondary	changes of miRNA between cardiotoxicity group and No cardiotoxicity	changes of miRNA between cardiotoxicity group and No cardiotoxicity	From the start of cyclophosphamide injection to1 month after the completion of injection